60 Degrees Pharmaceuticals (SCTP) Q2 2026 earnings summary

Executive summary

• Achieved a 106% year-over-year increase in Q2 product revenue to $208 thousand, driven by higher shipments and resolution of supply shortages.

• Gross margin declined to 27.3% from 50.4% due to higher costs and product mix changes.

• Operating expenses rose to $2.33 million, up 25% year-over-year, mainly from increased R&D and higher sales and promotion costs.

• Net loss for Q2 was $2.40 million ($0.90 per share), with a six-month net loss of $4.35 million.

• Company remains focused on commercialization of Arakoda, advancing babesiosis clinical trials, and ongoing collaborations in the U.S. and Australia.

Financial highlights

• Q2 2026 product revenue: $208 thousand (up from $101 thousand in Q2 2025).

• Gross profit: $57 thousand (Q2 2026), up from $51 thousand (Q2 2025).

• Gross margin: 27.3% (Q2 2026) vs. 50.4% (Q2 2025).

• Operating expenses: $2.33 million (Q2 2026), up from $1.86 million (Q2 2025).

• Net loss attributable to shareholders: $2.40 million (Q2 2026), $4.35 million (six months).

• Cash and equivalents: $1.02 million as of June 30, 2026.

Outlook and guidance

• Management projects sufficient funds to operate through early October 2026, factoring in July PIPE proceeds.

• Substantial doubt remains about ability to continue as a going concern beyond that period without additional capital.

• Future performance depends on successful clinical trials, regulatory approvals, and securing further equity financing.